Alirocumab for hypercholesterolaemia.
出版信息
Aust Prescr. 2019 Feb;42(1):29-31. doi: 10.18773/austprescr.2019.071. Epub 2018 Dec 13.
Abstract
摘要
相似文献
1
Alirocumab for hypercholesterolaemia.阿利西尤单抗用于治疗高胆固醇血症。
Aust Prescr. 2019 Feb;42(1):29-31. doi: 10.18773/austprescr.2019.071. Epub 2018 Dec 13.
2
Alirocumab for the treatment of hypercholesterolaemia.依洛尤单抗治疗高胆固醇血症。
Expert Rev Clin Pharmacol. 2017 Jun;10(6):571-582. doi: 10.1080/17512433.2017.1318063. Epub 2017 Apr 18.
3
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.ODYSSEY FH I和FH II：735例杂合子家族性高胆固醇血症患者接受阿利西尤单抗治疗78周的结果
Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1.
4
Alirocumab: First Global Approval.依洛尤单抗：全球首次获批。
Drugs. 2015 Sep;75(14):1699-705. doi: 10.1007/s40265-015-0469-8.
5
Two new lipid-regulating drugs.两种新型脂质调节药物。
Drug Ther Bull. 2016 Feb;54(2):18-21. doi: 10.1136/dtb.2016.2.0381.
6
7
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.阿利西尤单抗治疗 1 型或 2 型糖尿病伴高心血管风险的胰岛素治疗患者的疗效和安全性：ODYSSEY DM-INSULIN 试验的原理和设计。
Diabetes Metab. 2017 Oct;43(5):453-459. doi: 10.1016/j.diabet.2017.01.004. Epub 2017 Mar 24.
8
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.阿利西尤单抗在接受最大耐受剂量他汀类药物治疗但高胆固醇血症控制不佳的高心血管风险患者中的疗效和安全性：ODYSSEY COMBO II随机对照试验
Eur Heart J. 2015 May 14;36(19):1186-94. doi: 10.1093/eurheartj/ehv028. Epub 2015 Feb 16.
9
[PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent®].[前蛋白转化酶枯草溶菌素9（PCSK9）抑制：家族性高胆固醇血症、他汀类药物不耐受患者以及最终心血管风险最高的患者的新希望？聚焦于阿利西尤单抗（Praluent®）]
Vnitr Lek. 2015 Nov;61(11):946-51.
10
RE: Praluent (Alirocumab)-Induced Renal Injury.关于：普来鲁肽（阿利西尤单抗）所致肾损伤。
J Pharm Pract. 2018 Apr;31(2):138-139. doi: 10.1177/0897190017734429. Epub 2017 Oct 3.
本文引用的文献
1
Evolocumab.依洛尤单抗
Aust Prescr. 2016 Oct;39(5):180-182. doi: 10.18773/austprescr.2016.078. Epub 2016 Oct 1.
2
PCSK9 inhibitors - clinical applications.前蛋白转化酶枯草溶菌素9抑制剂——临床应用
Aust Prescr. 2016 Oct;39(5):168-170. doi: 10.18773/austprescr.2016.061. Epub 2016 Oct 1.
3
PCSK9 inhibitors - mechanisms of action.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂——作用机制
Aust Prescr. 2016 Oct;39(5):164-167. doi: 10.18773/austprescr.2016.060. Epub 2016 Oct 1.
4
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.一项III期随机试验，评估每4周一次300毫克阿利西尤单抗作为单一疗法或与他汀类药物联合使用：ODYSSEY CHOICE I。
Atherosclerosis. 2016 Nov;254:254-262. doi: 10.1016/j.atherosclerosis.2016.08.043. Epub 2016 Aug 31.
5
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.在未接受他汀类药物治疗的高胆固醇血症患者中，每 4 周给予 150mg 依洛尤单抗的疗效和安全性：ODYSSEY CHOICE II 研究。
J Am Heart Assoc. 2016 Sep 13;5(9):e003421. doi: 10.1161/JAHA.116.003421.
6
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.PCSK9 抑制剂依洛尤单抗和阿利西尤单抗的系统评价
J Manag Care Spec Pharm. 2016 Jun;22(6):641-653q. doi: 10.18553/jmcp.2016.22.6.641.
7
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.在他汀类药物不耐受患者中，阿利西尤单抗与依折麦布的疗效和安全性对比，并设他汀类药物再激发组：ODYSSEY ALTERNATIVE随机试验
J Clin Lipidol. 2015 Nov-Dec;9(6):758-769. doi: 10.1016/j.jacl.2015.08.006. Epub 2015 Aug 29.
8
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.ODYSSEY FH I和FH II：735例杂合子家族性高胆固醇血症患者接受阿利西尤单抗治疗78周的结果
Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1.
9
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.阿利西尤单抗联合阿托伐他汀与其他降脂治疗策略的比较：ODYSSEY OPTIONS I随机试验
J Clin Endocrinol Metab. 2015 Aug;100(8):3140-8. doi: 10.1210/jc.2015-1520. Epub 2015 Jun 1.
10
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.前蛋白转化酶枯草溶菌素/kexin 9型抑制剂阿利西尤单抗在接受最大耐受剂量他汀类药物治疗的高心血管风险患者中的疗效和安全性：ODYSSEY COMBO I研究
Am Heart J. 2015 Jun;169(6):906-915.e13. doi: 10.1016/j.ahj.2015.03.004. Epub 2015 Mar 13.
Zotero 插件